Treatment of pervasive developmental disorders with redox-active therapeutics
AssigneeEdison Pharmaceuticals, Inc.
InventorsGuy M. Miller, Viktoria Kheifets
Life of this patent
Estimating the term…
Abstract
Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.
Claims24
A method of reducing the symptoms associated with, or for treating or suppressing a pervasive developmental disorder (PDD) selected from autistic spectrum disorder (ASD), by administering a therapeutically effective amount or physiologically effective amount of a medical food, functional food, food supplement or dietary supplement comprising compositions of one or more compounds of Formula I:
- wherein,
- the bonds indicated with a dashed line are all single bonds or are all double bonds;
- R1, R2, and R3 are independently selected from H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen and CN;
- or a salt, a stereoisomer, or a mixture of stereoisomers thereof;
- and at least one of the group consisting of a physiologically or nutritionally acceptable carrier, adjuvant, excipient, buffer and diluent, to a patient in need thereof.
A method of reducing the symptoms associated with, or for treating or suppressing attention deficit/hyperactivity disorder (ADHD), by administering a therapeutically effective amount or physiologically effective amount of a medical food, functional food, food supplement or dietary supplement comprising compositions of one or more compounds of Formula I:
- wherein,
- the bonds indicated with a dashed line are all single bonds or are all double bonds;
- R1, R2, and R3 are independently selected from H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen and CN;
- or a salt, a stereoisomer, or a mixture of stereoisomers thereof;
- and at least one of the group consisting of a physiologically or nutritionally acceptable carrier, adjuvant, excipient, buffer and diluent, to a patient in need thereof.
A method of reducing the symptoms associated with, or of treating or suppressing pervasive developmental disorders (PDDs) or attention deficit/hyperactivity disorder (ADHD) in a patient in need of such treatment by administering a therapeutically or physiologically effective amount of one or more compounds of Formula I:
- wherein, the bonds indicated with a dashed line are all single bonds or are all double bonds;
- R1, R2, and R3 are independently selected from H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen and CN;
- or a salt, a stereoisomer, or a mixture of stereoisomers thereof.
Dependencies are inferred from the claim text.